ClinicalTrials.gg
RecruitingNCT06971614Updated Aug 18, 2026

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

A Phase 2 interventional study of T3011 in Nonmuscle-invasive Bladder Cancer, sponsored by ImmVira Pharma Co. Ltd. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by ImmVira Pharma Co. Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 163 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
147th of 715
160 · median 46
Started
2025
with 53 others
Phase 2
238 of 883
33 open now
Primary completion
2028-12
later than 210 of 266 live
Registered
812th of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 147th largest by planned enrollment of the 715 interventional ones that give a count, is one of 54 that started in 2025, is one of 238 in phase 2, reaches primary completion later than 210 of the 266 other live ones, and was the 812th registered.

Urinary Bladder Neoplasms

1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

163 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.

Read the detailed description

In Cohort A, participants will be enrolled with pathologically confirmed high-risk non-muscle invasive bladder cancer (NMIBC) (CIS with or without Ta or T1 papillary) which is unresponsive to BCG treatment.

In Cohort B, participants will be enrolled with pathologically confirmed high-risk non-muscle invasive bladder cancer (NMIBC) (Ta/T1 papillary without CIS) which is unresponsive to BCG treatment.

In Cohort C, participants will be enrolled with pathologically confirmed high-risk non-muscle invasive bladder cancer (NMIBC) (CIS with or without Ta or T1 papillary) which has previously been exposed to BCG and is unresponsive to chemotherapy treatment.

In Cohort D, participants will be enrolled with pathologically confirmed intermediate/high-risk non-muscle invasive bladder cancer (NMIBC) (Ta/T1 papillary without CIS) which has previously been exposed to BCG and is unresponsive to chemotherapy treatment.

In all cohorts, study treatment will be administered as a weekly induction course for the first 6 weeks.

For high-risk participants, a reinduction course administered to participants who have residual CIS or high-grade Ta disease at the 3-month evaluation. Following induction, If the tumor assessment indicates CR or no recurrence the participant enters the maintenance phase, T3011 is administered once every 3 weeks (Q3W).

For intermediate-risk participants, a reinduction course administered to participants who have low-grade Ta disease at the 3-month evaluation. Following induction, the participant achieving no recurrence (e.g., no tumor) enters the maintenance phase, T3011 is administered once every 3 weeks (Q3W).

Disease status will be assessed using cystoscopy, urine cytology, histopathology (if performed), and imaging examinations (if performed) every 3 months during treatment period or until disease recurrence.

03

Conditions studied

  • Nonmuscle-invasive Bladder Cancer

Keywords

  • Nonmuscle-invasive Bladder Cancer
  • Herpes Virus T3011 Injection
  • BCG-Unresponsive
  • BCG-Exposed
  • Chemotherapy-Unresponsive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants may enter the study only if they meet all the following criteria:

  1. Male or female, aged ≥18 years at the time of signing the ICF.
  2. The participants will need to meet the following criteria:

    1. Participants with a confirmed diagnosis of NMIBC (Ta, T1 and/or Cis).
    2. During the study, the participants must voluntarily comply with the study-specified cystoscopy, urine cytology and randomized .
  3. All toxicities caused by prior radiotherapy, chemotherapy or other treatments have recovered to Grade ≤1 ( 5.0) (except for alopecia), including but not limited to urinary tract infection, urinary tract irritation, and macroscopic hematuria; participants with Grade >1 anti-neoplastic treatment-related toxicities during the screening period may be enrolled after discussion of the investigators and the sponsor.
  4. (ECOG) performance status score of 0-2.
  5. Expected survival ≥24 weeks.
  6. Laboratory test values meeting the following requirements :

    1. Hematology ≥1.5×10\^9/L. count ≥75×10\^9/L. (HGB) ≥90 g/L.
    2. Renal function ≥60 mL/min (based on Cockcroft-Gault equation for calculation)
    3. Hepatic function Serum total (TBIL) ≤1.5×. Asparate aminotransferase () and alanine transaminase (ALT) ≤2.5×ULN Serum ALB ≥30 g/L.
    4. Coagulation function (INR) or prothrombin time (PT) ≤1.5×ULN. Activated partial thromboplastin time (aPTT) ≤1.5×ULN.
  7. For women of (WOCBP), the serum pregnancy test prior to the first dose must be negative and the potential participant must promise to use medically acceptable and effective methods of . after signing the ICF until at least 6 months after the last dose.
  8. Male participants of child-bearing potential must agree to use medically acceptable and effective methods of contraception after signing the ICF until at least 6 months after the last dose; in addition, male potential participants must agree not to donate sperm during this period.
  9. Participants who understand and voluntarily sign the written ICF and are willing and able to comply with all trial requirements.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will not be allowed to participate in this study:

  1. Participants meet the following criteria:

    1. Concurrent or prior history of muscle-invasive (muscularis propria) or bladder cancer.
    2. Urothelial carcinoma of the upper genitourinary tract or prostatic urethra within 24 months prior to product.
    3. Having received chemotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, investigational product or other anti-neoplastic therapies within 4 weeks prior to investigational product.
    4. Having received radiotherapy within 2 weeks prior to investigational product.
  2. Planning to receive any anti-neoplastic therapy other than the investigational products during this study.
  3. A history of allergic reactions to HSV-1, IL-12, or antibodies or biological components similar to them, or known allergic reactions to any component of the T3011 formulation.
  4. A history of or imaging-confirmed brain metastasis , , or spinal cord compression.
  5. Concurrent or prior history of other than that treated in this study.
  6. History or evidence of high-risk cardiovascular diseases, including but not limited to:

    1. Serious cardiac rhythm or conduction abnormalities.
    2. Acute myocardial infarction, unstable angina, or stroke, etc., developing within 6 months prior to the first dose of the investigational products.
    3. Coronary angioplasty or stenting within 6 months prior to the first dose of the investigational products.
    4. (NYHA) criteria-defined cardiac function > Class II; echocardiogram-documented cardiac valve morphological abnormalities (Grade ≥2).
    5. (LVEF) ˂lower limit of normal (LLN) of the study site, or ˂ 50% if no LLN is set at the site.
    6. Poorly controlled blood pressure .
  7. The following prior or concurrent immune disorders that in the investigator's opinion would pose unpredictable risks to the participants:

    1. Immune-related pneumonia or other immune-related adverse reactions of Grade ≥3 developing with prior immunotherapy (including but not limited to PD-1/PD-L1).
    2. Concurrent active immune diseases requiring treatment with systemic (excluding diseases not requiring intervention such as vitiligo and diseases treatable by other alternative drugs such as hypothyroidism that is treated with thyroid hormone replacement therapy originally), or concurrent immune diseases requiring treatment with systemic immunosuppressants that have the potential to recurrence (e.g., systemic lupus erythematosus).
    3. Other concurrent diseases require treatment with systemic immunosuppressants.
  8. Unexplainable fever >38.5℃ during the screening or on the day of treatment (fever judged as tumor-induced by the investigator is eligible for enrollment) that in the investigator's opinion will affect the participation in this trial or interfere with the efficacy assessment.
  9. The following persistent or active infections: (HIV) antibody-positive, surface antigen [HBsAg] positive with HBV DNA level ≥2000 IU/mL, virus (HCV) antibody positive with detectable HCV RNA, and other active infections requiring systemic treatment.
  10. Prior history of splenectomy or organ transplantation.
  11. Having previously received treatment with oncolytic virus (e.g., T-VEC, CG0070).
  12. Requiring oral or intravenous use of anti-herpes virus drugs, including but not limited to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscarnet, and cidofovir (except for those to be used locally, such as topically), during the study.
  13. Participants with known psychiatric disorders that may affect compliance in trial or with poor compliance.
  14. Participants with a history of drug abuse (including "recreational use") or substance abuse (including alcohol) within one year prior to signing ICF.
  15. Being pregnant or breast feeding, or planning to become pregnant or give birth during this trial.
  16. Having received any within 4 weeks prior to investigational product or planning to receive such vaccines during the study.
  17. Having undergone a major surgery.
  18. Any diseases that at the investigator's discretion may confound the trial results, interfere with the participation in the entire trial, and/or would make participating in the trial not in the participant's best interest, or a medical history with treatment or laboratory abnormalities, or any other circumstances that would make it inappropriate for the participant to be enrolled.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    T3011

    T3011 will be given once a week (QW) for 6 weeks during the induction treatment course, the following 6 weeks are only for observation and then the 3-month efficacy assessment will be conducted. During the maintenance period, T3011 will be given every 3 weeks (Q3W) until about 24 months or meeting the criteria for treatment discontinuation.

    Biological: T3011

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Response Rate in patients with CIS

    Time frame: 3,6,12 months time point from the date of the first dose of T3011

  2. Recurrence Free Survival Rate in patients with Ta/T1 (without CIS)

    Time frame: 3,6,12 months time point from the date of the first dose of T3011

  3. Incidence rates of Grade ≥3 treatment-related adverse events (TRAEs)

    Time frame: 24 months

  4. Incidence rates of TRAEs leading to treatment discontinuation, dose modification or treatment interruption.

    Time frame: 24 months

Secondary outcomes

  1. Complete Response Rate in patients with CIS

    Time frame: 18,24 months time point from the date of the first dose of T3011

  2. Recurrence Free Survival Rate in patients with Ta/T1 (without CIS)

    Time frame: 18,24 months time point from the date of the first dose of T3011

  3. Safety Endpoints

    * Incidence rates of Grade ≥3 treatment-emergent adverse events (TEAEs) * Incidence rates of all grades of TRAEs * Incidence rates of AEs leading to treatment discontinuation, dose modification or treatment interruption

    Time frame: 24 months

07

Study locations

9 of 9 sites recruiting
  • East Valley Urology Center
    Queen Creek, Arizona 85140, United States
    Recruiting
    • Harpreet Wadhwa, MD · Contact
  • Tower Urology
    Los Angeles, California 90048, United States
    Recruiting
    • David Josephson, MD · Contact
  • Advent Health Medical Group Urology
    Orlando, Florida 32803, United States
    Recruiting
    • Zachary Smith, MD · Contact
  • Florida Urology Partners, LLP
    Tampa, Florida 33615, United States
    Recruiting
    • Osvaldo Padron, MD · Contact
  • Rutgers Cancer Institute
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Vignesh Packiam, MD · Contact
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
    Recruiting
    • Alberto Martini, MD · Contact
  • Helios Clinical Research
    Middleburg Heights, Ohio 44130, United States
    Recruiting
    • Lawrence Gervasi, MD · Contact
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
    • Shifeng Mao, MD · Contact
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
    • Neal Shore, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 39 industry-sponsored phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 42 months is above that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2025
First posted
May 14, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
May 31, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06971614
Lead sponsor
ImmVira Pharma Co. Ltd
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Jun 9, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Jasmine Yang
Contact
xu.yang@immviragroup.com
86-512-66202028

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011

Start the discussion